TherapeuticsMD reports 8,500 RSU award to director on Nov 3, 2025
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TherapeuticsMD (TXMD) reported insider equity activity. Director Tommy G. Thompson received 8,500 restricted stock units (RSUs) on November 3, 2025.
Each RSU represents the right to receive one share of common stock and will vest on November 3, 2028. Following the grant, 8,500 derivative securities were beneficially owned on a direct basis.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Thompson Tommy G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 8,500 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 8,500 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did TXMD disclose in this Form 4?
A director received 8,500 RSUs on November 3, 2025.
How many RSUs were awarded to the TXMD director?
The filing reports 8,500 restricted stock units.
When do the RSUs vest for TXMD (TXMD)?
The RSUs will vest on November 3, 2028.
What does each RSU represent for TXMD?
Each RSU represents a right to receive one share of common stock.
What is the ownership form after the transaction?
The 8,500 derivative securities are held on a direct basis.
Who is the reporting person in the TXMD Form 4?
Tommy G. Thompson, serving as a Director.